#The outcome of the sofosbuvir Based Therapy in the treatment of Hepatitis C Virus Genotype 4 in Egyptian patients
Waleed Abdul Fattah Ismail¹, Amr Shaaban Hanafy ¹, Mohammed Abdelsattar ²
1: Assistant professor of internal medicine,
gastroenterology and hepatology unit, faculty
of medicine, Zagazig University.
2: Internal Medicine Department- Mansura University.
DOI:
https://dx.doi.org/10.52378/alkj/2738
Corresponding author: Amr
Shaaban Hanafy,
Assistant
professor of internal medicine, gastroenterology and hepatology unit, faculty
of medicine, Zagazig University.
Sharkia, Zagazig, 44519 40- Mostafa Fouad St., Cellphone: +201100061861
Abstract
Background
and aim
There
have been significant advancements during the last few years, with large numbers of ongoing trials with various direct-acting
antivirals (DAA) showing high potency against the hepatitis C virus (HCV). The aim was to show the effectiveness and
side effects of Sofosbuvir-based therapy in treating HCV genotype 4 in Egyptian patients and compare its results
with the international results.
Methods
The
study included 740 patients with chronic HCV. The study population consisted of three groups: Group (1): included 240
patients treated with sofosbuvir 400 mg
plus Peginterferon α2a and weight-based ribavirin for 12 weeks. Group (2): had
250 patients treated with sofosbuvir 400
mg and weight-based ribavirin for 24 weeks. Group (3): involved 250 patients treated
with sofosbuvir 400 mg and simeprevir 150 mg once daily for 12weeks.
Results
Sustained
virological response (SVR) occurred in 83.3% of
the triple therapy group. In the dual
therapy group, SVR occurred in 64% of patients.
In the Simeprevir-Sofosbuvir group, SVR was
achieved in 96% of patients,
with statistically significant differences among the studied groups (p=0.015).
Multivariate logistic regression analysis showed that treatment with simeprevir and sofosbuvir was associated with higher rates of SVR with an odds ratio of 12.5. Serum creatinine
shows a negative correlation with an odds ratio of 3.1; MELD score showed
a negative correlation with an odds ratio of 1.5.
Conclusion
Sofosbuvir-based
therapy has satisfactory results for the
treatment of hepatitis C virus genotype 4 with lesser complications
Comments